Autres langues Keros Therapeutics, Inc.

Actions

KROS

US4923271013

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 21/09/2026			Varia. 5j.	Varia. 1 janv.
11,48 ^USD	+2,59%		+2,41%	-43,61%

08/09	Keros Therapeutics approuve un rachat d'actions de 5 millions de dollars	MT
08/09	Keros Therapeutics, Inc. (NasdaqGM:KROS) annonce un rachat d'actions pour un montant de 5 millions de dollars.	CI

Autres langues

08/09	Keros Therapeutics Approves $5 Million Share Buyback
08/09	Keros Therapeutics, Inc. announces an Equity Buyback for $5 million worth of its shares.
08/09	Keros Therapeutics Announces $5 Million Share Repurchase Authorization
08/09	Keros Therapeutics, Inc. authorizes a Buyback Plan.
03/08	Keros Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
03/08	Keros Therapeutics Reports Second Quarter 2026 Financial Results
30/07	Keros Therapeutics to Receive $20 Million Development Milestone Payment From Takeda
30/07	Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda
30/07	Keros Therapeutics, Inc. Announces to Receive Development Milestone Payment from Partner Takeda Pharmaceutical Company Limited
22/07	Keros Therapeutics, Inc. Announces CFO Changes
22/07	Keros Therapeutics, Inc. Announces Appointment of Annita Tanini as Interim Principal Accounting Officer, Effective August 4, 2026
29/06	Keros Therapeutics, Inc.(NasdaqGM:KROS) added to Russell Microcap Value Benchmark Index
29/06	Keros Therapeutics, Inc.(NasdaqGM:KROS) added to Russell 3000E Index
29/06	Keros Therapeutics, Inc.(NasdaqGM:KROS) added to Russell Microcap Index
29/06	Keros Therapeutics, Inc.(NasdaqGM:KROS) added to Russell 2000 Value-Defensive Index
29/06	Keros Therapeutics, Inc.(NasdaqGM:KROS) added to Russell 2000 Defensive Index
25/06	Keros Therapeutics, Inc. Announces Appointment of Anne Prener as Director, Effective July 1, 2026
25/06	Keros Therapeutics Appoints Anne Prener to its Board of Directors
01/06	Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference
14/05	Keros Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
14/05	Keros Therapeutics Reports Recent First Quarter 2026 Financial Results
30/03	TGFB Inhibitors Competitive Landscape & Pipeline 2026: Emerging Therapies, Leading Companies, and Future Outlook
23/03	Keros Therapeutics, Inc.(NasdaqGM:KROS) dropped from S&P Biotechnology Select Industry Index
09/03	Keros Therapeutics, Massachusetts Hospital Partner to Design Trial for Potential Lou Gehrig's Disease Treatment
09/03	Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS